A phase II study of docetaxel in combination with ZD 1839 (Iressa) [gefitinib] in previously treated patients with metastatic pancreatic cancer

Trial Profile

A phase II study of docetaxel in combination with ZD 1839 (Iressa) [gefitinib] in previously treated patients with metastatic pancreatic cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Oct 2017

At a glance

  • Drugs Docetaxel (Primary) ; Gefitinib (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Nov 2009 Actual end date (1 Mar 2009) added as reported by ClinicalTrials.gov.
    • 03 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Dec 2007 The expected completion date for this trial is now 1 Jun 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top